Can Botulinum Toxin Be Used for Migraine? What Patients Should Know

If you’ve heard that “Botox can treat migraines,” you’ve heard something based in real medicine.

But there’s an important distinction most social-media posts leave out.

Botulinum toxin isn’t one single product.

Botulinum toxin type A exists in several formulations.

The most established evidence for chronic migraine prevention involves onabotulinumtoxinA, commonly known by the brand name Botox®.

The PREEMPT clinical program and subsequent research established onabotulinumtoxinA as an important preventive treatment option for chronic migraine. More recent research continues to evaluate treatment approaches and outcomes.

But that evidence should not automatically be assigned to every botulinum toxin formulation.

What about Dysport?

Dysport® contains abobotulinumtoxinA, another botulinum toxin type A formulation.

Its use for migraine prevention is off-label in the United States.

“Off-label” does not mean that a clinician is prohibited from using a medication that way. It means the particular use is not an FDA-approved indication for that product.

And that distinction matters.

At SKM, we don’t take statistics from studies performed with Botox and present them to patients as though they were Dysport studies.

That’s not how evidence-based care should work.

So why would SKM consider it?

Medicine frequently involves evaluating available evidence, the individual patient, potential benefits, risks and alternatives.

For selected patients, SKM may use Dysport as part of an individualized migraine treatment plan when the treating provider determines that its off-label use is clinically appropriate.

That decision happens after evaluation, not because someone clicked “buy” online.

What happens during a Migraine Consultation?

We want to understand your migraine pattern before talking about a procedure.

That can include questions about:

• headache days
• migraine days
• severity
• functional impact
• rescue medication use
• previous treatments
• relevant medical and medication history

Not every person with headaches is an appropriate candidate for treatment at SKM.

And not every migraine patient should receive the same treatment.

That’s why the consultation is the front door.

Why we track outcomes

If we treat something medically, we should be able to ask whether it’s actually helping.

SKM’s migraine follow-up therefore looks beyond:

“Do you feel better?”

We can evaluate changes in headache and migraine frequency, severity, function, rescue-medication use, treatment response and adverse effects.

That allows the next decision to be informed by what actually happened.

One final distinction

SKM doesn’t advertise Dysport as an FDA-approved migraine treatment because it isn’t one.

We offer migraine care.

That means evaluating the problem, determining whether treatment at SKM is appropriate, discussing benefits, risks and alternatives, and following the patient’s response over time.

The drug is one possible tool.

The care plan comes first.

Dysport® (abobotulinumtoxinA) is not FDA-approved for the prevention of migraine. Its use for migraine at SKM is off-label. Treatment is provided only when clinically appropriate following medical evaluation.

References

Nag S, Kennedy P, Weber KD, Janis JE. Comparing Phase III Research Evaluating Migraine Prophylaxis Therapy (PREEMPT) and Targeted Approaches for OnabotulinumtoxinA in Chronic Migraine Treatment. Plast Reconstr Surg Glob Open. 2026 May 11;14(5):e7678. doi: 10.1097/GOX.0000000000007678. PMID: 42221291; PMCID: PMC13218676.